



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

A more Patent Application of

ASHTON et al.

Atty. Ref.: 620-401

Serial No. 10/556,901

Group: unknown

Filed: November 15, 2005

Examiner: Unknown

For: GLYOXALASE INHIBITORS

\* \* \* \* \*

Commissioner for Patents  
 P.O. Box 1450  
 Alexandria, VA 22313-1450

December 16, 2005

Sir:

**INFORMATION DISCLOSURE STATEMENT**

1. **PTO-1449 Pursuant to 37 CFR 1.97(b)**  
 [within 3 months of filing or prior to 1st Office Action on the merits]  
 N/C

2.(a) **Statement Pursuant to 37 CFR 1.97(c)**  
 [before Final Office Action or Allowance (requires Rule 97(e)  
 Statement or Rule 17(p) fee)]  
 N/C

2 .(b) **Fee Payment Pursuant to 37 CFR 1.97(c)**  
 [before Final Office Action or Allowance (requires Rule 97(e)  
 Statement or Rule 17(p) fee)]  
 \$180.00

3. **Pursuant to 37 CFR 1.97(d)**  
 [after Final Office Action or Allowance (requires Rule 97(e)  
 Statement and Rule 17(p) fee), but before final fee payment]  
 \$180.00

The following are submitted in the above-identified application in compliance with 37 C.F.R. §§ 1.97 and 1.98:

4. A list of documents on Form PTO-1449 together with copies of each identified document and a translation or a concise explanation of each non-English language document (such as a Search Report) is enclosed herewith.

This paper is submitted in accordance with:

5. 37 CFR 1.97(b): [within 3 months of filing or prior to 1st Office Action]

6. 37 CFR 1.97(c): [before Final Office Action or Allowance, whichever is earlier]; and

a) The required Statement made in item 8 below; or

b) The \$180.00 fee specified in 37 CFR §1.17(p) for submission of this Information Disclosure Statement is authorized in item 9 below.

7. 37 CFR §1.97(d): [after Final Office Action or Allowance (requires Rule 97(e) Statement and Rule 17(p) fee), but before final fee payment]; and

a) The fee (\$180.00) required by 37 CFR §1.17(p) is submitted herewith; and

b) The required Statement is stated in item 8 below.

8. Statement under 37 CFR 1.97(e)


a) The undersigned attorney of record hereby certifies under 37 C.F.R. §1.97(e) that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement (each item contained in this IDS was the first citation of that item by a foreign patent office in a counterpart foreign application which occurred no more than three months prior to the filing of this IDS); or

b) No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this Statement, after making reasonable inquiry, no item of information contained in this Statement was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

9. Please charge all deficiency fees associated with the submission of this Information Disclosure Statement and any other fees applicable to this application to Deposit Account No. 14-1140. An original and one (1) copy of this document are enclosed.

Respectfully submitted,  
NIXON & VANDERHYE P.C.

By:

  
B.J. Sadoff

Reg. No. 36,663

901 North Glebe Road, 11th Floor  
Arlington, VA 22203-1808  
Telephone: (703) 816-4000  
Facsimile: (703) 816-4100



## INFORMATION DISCLOSURE

ATTY. DOCKET NO. SERIAL NO.

## CITATION

620-401

10/556,901

APPLICANT

ASHTON et al.

(Use several sheets if necessary)

FILING DATE

GROUP

November 15, 2005

unknown

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
/N.C./	4,898,870	02/1990	Narutomi et al			

## FOREIGN PATENT DOCUMENTS

DOCUMENT	DATE	COUNTRY	TRANSLATION		
			CLASS	SUBCLASS	YES
/N.C./ WO 99/35128	07/1999	WIPO			


## OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)

/N.C./	Beilstein BRN: 5300594, 5139287, 5137246 & Shestopalov et al, J. Org. Chem. USSR, 1984, 1818-1827
✓	Beilstein BRN: 5133758 & Rodinovskaya et al, J. Org. Chem. USSR, Vol. 21, No. 11, 1985, 2230-2235
✓	Beilstein BRN: 4489731 & Rodinovskaya et al, Chem. Heterocycl. Compounds (Engl. Transl.), 1988, 658-664
✓	Beilstein BRN: 2047546 & Hudgins et al, Biochem. Pharmacol., Vol. 52, No. 8, 1996, 1227-1233
✓	Beilstein BRN: 7543266 & Gribble et al, J. Med. Chem., Vol. 39, No. 18, 1996, 3569-3584
✓	Beilstein BRN: 1994106, 246624 & Child et al, Arzneim Forsch, Vol. 30, No. 4a, 1980, 695-702
✓	Beilstein BRN: 3593422 & Chenard et al, J. Med. Chem., Vol. 33, No. 3, 1990, 1077-1083
✓	Beilstein BRN: 2334448 & Lohse et al, J. Agric. Food Chem., Vol. 48, No. 12, 2000, 5913-5923
✓	Thornalley et al, Crit. Rev. Oncol. Hematol., Vol. 20, 1995, 99-128
✓	Sakamoto et al, Clin. Cancer Res., Vol. 7, 2001, 2513-2518
	Davidson et al, The Journal of Urology, Vol. 161, 1999, 690-691
	Samadi et al, Urology, Vol 57, 2001, 183-187
	Ranganathan et al, Biochimica et Biophysica Acta, Vol 1182, 1993, 311-316
	Sakamoto et al, Blood, Vol. 95, 2000, 3214-3218
	Rulli et al, Breast Canc. Res. Treat, Vol 66, 2001, 67-72
	Thornalley et al, Gen. Pharmacol., Vol 27, No. 4, 1996, 565-573
	Johansson et al, Mol. Pharmacol., Vol. 57, 2000, 619-624
	Thornalley et al, J. Med. Chem., Vol. 39, 1996, 3409-3411
✓	Kalsi et al, J. Med. Chem., vol. 43, No. 21, 2000, 3981-3986
/N.C./	Sharkey et al, Cancer Chemother. Pharmacol., Vol. 46, 2000, 156-166

Examiner /Nizal Chandrakumar/ Date Considered 01/15/2009

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Form PTO-FB-A820 (Also PTO-1449)



**INFORMATION DISCLOSURE** ATTY. DOCKET NO.  **SERIAL NO.**  
**CITATION** 620-401 10/556,901

(Use several sheets if necessary)

ASHTON *et al*

**APPENDANT**

**SERIAL NO.**

10/556,901

ASHTON et al.

FILED DATE

## GROUP

November 15, 2005

unknown

## U.S. PATENT DOCUMENTS

SEARCHED DOCUMENTS						INDEXED	
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

## FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS							TRANSLATION	
DOCUMENT	DATE	COUNTRY		CLASS	SUBCLASS	YES	NO	

**OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)**

Examiner /Nizal Chandrakumar/ Date Considered 01/16/2009

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Form PTO-FB-A820 (Also PTO-1449)